LM-302

DRUG6 trials

Conditions

Advanced Solid TumorBiliary Tract CancerCandonilimabChemotherapy EffectClaudin 18.2Locally Advanced or Metastatic GC and GCJ AdenocarcinomaMalignant Neoplasms of Digestive OrgansPancreatic Cancer

Phase 1

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

CompletedNCT05001516

Turning Point Therapeutics, Inc.Advanced Solid Tumor

Start: 2021-12-29End: 2024-01-04Updated: 2024-04-17

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

CompletedNCT05188664

LaNova Australia Pty LimitedAdvanced Solid Tumor

Start: 2022-05-10End: 2023-11-14Updated: 2025-02-17

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Active, not recruitingNCT05994001

Shanghai Zhongshan HospitalBiliary Tract Cancer, Candonilimab, Claudin 18.2

Start: 2023-08-01End: 2026-12-01Updated: 2026-02-18

Phase 2

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

RecruitingNCT05934331

LaNova Medicines Zhejiang Co., Ltd.Malignant Neoplasms of Digestive Organs

Start: 2023-07-27End: 2028-07-01Target: 276Updated: 2025-09-12

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Not yet recruitingNCT07108504

Shanghai Zhongshan HospitalChemotherapy Effect, Pancreatic Cancer

Start: 2025-08-10End: 2028-08-10Target: 30Updated: 2025-08-07

Phase 3

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active, not recruitingNCT06351020

LaNova Medicines Zhejiang Co., Ltd.Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Start: 2024-06-24End: 2026-12-15Updated: 2026-02-06

Related Papers

Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.

Journal of Clinical Oncology2026-05-27

Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results.

Journal of Clinical Oncology2025-05-283 citations

Two stage, multi-center trial of cadonilimab and LM-302 for patients with CLDN18.2+ biliary tract cancer (BTC) that failed chemotherapy and PD-(L)1 antibody (ZSAB-Calm).

Journal of Clinical Oncology2024-06-013 citations